Procept Biorobotics Corp - PRCT STOCK NEWS

PROCEPT BioRobotics (Nasdaq: PRCT) announced its participation at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, featuring presentations on Aquablation therapy for BPH treatment. The event, taking place April 26-29, will showcase scientific presentations and interactive workshops highlighting long-term outcomes, safety, and durability of their HYDROS Robotic System.

The company's booth #1431 will host surgeon-led presentations, hands-on workshop sessions, and a dedicated resident-focused session. Notable thought leader presentations include discussions on BPH practice transformation, data-driven decisions, and optimizing BPH care pathways. The scientific program features multiple sessions on BPH surgical therapy and new technology, including the WATER IV Prostate Cancer study comparing Aquablation versus Radical Prostatectomy.

PROCEPT BioRobotics (PRCT) reported strong Q1 2025 financial results with total revenue of $69.2 million, up 55% year-over-year. The company's U.S. performance showed significant growth with handpiece and consumables revenue reaching $38.0 million (61% increase) and system revenue of $18.7 million (31% increase). International revenue doubled to $8.9 million.

The company sold 43 new robotic systems in the U.S., bringing the total U.S. install base to 547 systems. Gross margin improved to 64% compared to 56% in the prior year. Despite operating expenses increasing to $71.6 million, the net loss decreased to $24.7 million from $26.0 million year-over-year.

PROCEPT raised its 2025 revenue guidance to $323 million, representing 44% growth, and expects a full-year gross margin of approximately 64.5%.

PROCEPT BioRobotics (Nasdaq: PRCT) announced an upcoming investor event scheduled for April 25, 2025, from 8:00am to 9:30am PT at the Aria Resort in Las Vegas during the American Urological Association Annual Meeting.

The event will feature presentations from the company's leadership team, including CEO Reza Zadno, CFO Kevin Waters, CCO Sham Shiblaq, and CTO Barry Templin. Clinical perspectives will be provided by distinguished physicians: Dr. Inderbir Gill from USC Urology, Dr. Brian Helfand from Endeavor Health, and Dr. Gerald Park from Kansas City Urology Care.

The event will be accessible via live webcast on the company's investor relations website, with recordings available for at least 90 days afterward.

PROCEPT BioRobotics (NASDAQ: PRCT) announced results from the WATER III trial comparing Aquablation therapy to laser enucleation for treating large prostates (80-180mL). The international study, involving 186 men between December 2020 and September 2024, revealed that Aquablation therapy achieved similar symptom relief while demonstrating significantly better outcomes in key areas:

• Lower ejaculatory dysfunction rates (14.8% vs 77.1%)
• Lower stress incontinence rates (0% vs 9.1%)
• 0% procedural transfusion rate

The trial results, presented at the European Association of Urology 2025 Annual Congress in Madrid, add to Aquablation therapy's clinical foundation, which includes the WATER study, WATER II, and over 150 peer-reviewed publications.

PROCEPT BioRobotics (Nasdaq: PRCT) has announced two upcoming investor events in April 2025. The company will host an in-person investor event on April 25, 2025, from 8:00am to 9:30am PT at the Venetian Hotel in Las Vegas during the American Urological Association Annual Meeting.

The event will feature presentations from the company's management team, including the CEO, CFO, CCO, and CTO. Clinical perspectives will be provided by distinguished physicians from USC Urology, Endeavor Health, and Kansas City Urology Care.

Additionally, PROCEPT BioRobotics will report its Q1 2025 financial results on April 24, 2025, before market open, followed by a conference call at 8:00 a.m. ET. Both events will be accessible via webcast on the company's investor relations website, with recordings available for at least 90 days after the events.

PROCEPT BioRobotics (PRCT) reported strong Q4 2024 financial results with total revenue of $68.2 million, up 57% year-over-year. The company sold 60 new robotic systems in the US at an average price of $460,000. U.S. system revenue reached $27.6 million (+67%), while handpiece revenue grew to $29.3 million (+36%).

Full-year 2024 revenue was $224.5 million, representing 65% growth from 2023. The company achieved significant milestones including FDA 510(k) clearance for the HYDROS Robotic System and FDA-IDE approval for the WATER IV PCa prostate cancer study.

For 2025, PROCEPT projects revenue of approximately $320 million (+42% YoY) with an expected gross margin of 64.5%. Q4 2024 saw challenges with an acute saline shortage affecting 10-20% of Aquablation procedures.

PROCEPT BioRobotics (PRCT), a surgical robotics company specializing in urology solutions, has announced key upcoming events. The company will release its Q4 2024 financial results on February 25, 2025, after market close, followed by a conference call at 4:30 p.m. Eastern Time.

Additionally, management will participate in two significant healthcare conferences: the TD Cowen 45th Annual Healthcare Conference on March 4, 2025, at 1:10 p.m. ET, and the 2025 Leerink Partners Healthcare Conference on March 11, 2025, at 3:00 p.m. ET. Live webcasts and archived recordings of all events will be available on the company's investor relations website for at least 90 days.

PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urological solutions, has announced its participation in the 36th Annual Piper Sandler Healthcare Conference in New York City. The management team will deliver a presentation on Wednesday, December 4 at 8:30 a.m. Eastern Time.

The presentation will be accessible through a live webcast on the company's investor relations website. Interested parties can access the webcast recording for up to 90 days after the event through the company's website at https://ir.procept-biorobotics.com.

PROCEPT BioRobotics (NASDAQ: PRCT) has announced the pricing of its public offering of 1,923,076 shares of common stock at $91.00 per share, aiming to raise approximately $175 million in gross proceeds. A selling stockholder has granted underwriters a 30-day option to purchase up to an additional 288,461 shares. The offering, expected to close around October 31, 2024, is being managed by BofA Securities, Piper Sandler, and Morgan Stanley. The company will not receive proceeds from shares sold by the selling stockholder.